COYA

Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

Retrieved on: 
Thursday, September 7, 2023
Research, Neurology, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, DNA, Travel, EPHS, Macrophage, FASL, Cancer, Targeted drug delivery, Inflammation, Biomedical engineering, COYA, Plasma, Biomedicine, Coya, Engineering, Apoptosis, Epitope, Mouse, CMU, Exosome, Therapy, Pharmaceutical industry, Vaccine, Regulatory T cell

It was also demonstrated that CTLA-4-Treg exosomes exhibited far better cell uptake then non-modified Treg EVs in representative immune cells, macrophages (J7774 murine cell line) and T-cells (human Jurket cell line).

Key Points: 
  • It was also demonstrated that CTLA-4-Treg exosomes exhibited far better cell uptake then non-modified Treg EVs in representative immune cells, macrophages (J7774 murine cell line) and T-cells (human Jurket cell line).
  • Previously, using the same technology, CMU demonstrated applications in Oncology by engineering mesenchymal derived exosomes with an immunomodulatory apoptotic inducing protein, Fas Ligand (FAS-L).
  • Treg-derived exosomes share many of the properties of the parent Treg cells making them able to modulate physiological and pathophysiological processes.
  • Delivering EPHs to sites of inflammation or epitopes that drive specific diseases, while delivering customized loads, enables the next generation of selectively targeted and potent Treg-derived exosomes.

Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies

Retrieved on: 
Thursday, August 31, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, IIT, Host response to cancer therapy, CCL2, Clinical trial, Inflammation, Biomarker, COYA, Oxidative stress, HIV disease progression rates, Patient, Coya, Structure factor, Blood, Neurodegenerative disease, Therapy, ALS, Neuroinflammation, Disease, Pharmaceutical industry, Medical imaging, Regulatory T cell

The publication reports the analyses of blood biomarker data from a cross sectional cohort of sporadic ALS patients (n = 30) and healthy controls (n=10) and from two investigator-initiated clinical studies (IIT) (n=11).

Key Points: 
  • The publication reports the analyses of blood biomarker data from a cross sectional cohort of sporadic ALS patients (n = 30) and healthy controls (n=10) and from two investigator-initiated clinical studies (IIT) (n=11).
  • In the IIT studies, patients were treated with expanded Treg cell therapy in combination with low-dose interleukin-2 (IL-2).
  • As previously reported, patients from these two trials experienced amelioration of disease progression with corresponding increased Treg numbers and suppressive function.
  • Evidence strongly supports the role of inflammation and oxidative stress in the severity and rate of disease progression in ALS.

Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023

Retrieved on: 
Friday, August 25, 2023
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, COYA, CMU, Therapy, Therapeutic Targets Database, Biomedicine, Biomedical engineering, Medical device

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, will discuss novel proof of concept data in his presentation, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, will discuss novel proof of concept data in his presentation, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023.
  • The meeting registration and agenda can be located here.

Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, DNA, Saskatchewan River Sturgeon Management Board, International Federation of Pharmaceutical Manufacturers & Associations, Bayer, United States of Europe, Pharmaceutical Research and Manufacturers of America, Pharmacy, Bristol Myers Squibb, Science, COYA, Regulatory T cell, EFPIA, Regulation, Therapy, Pharmaceutical industry, Pfizer

Coya will leverage Mr. Weinand’s extensive experience, connections, and judgement to guide Coya’s strategic discussions and development programs.

Key Points: 
  • Coya will leverage Mr. Weinand’s extensive experience, connections, and judgement to guide Coya’s strategic discussions and development programs.
  • Mr. Weinand presently serves as the Chairman of the Board of Directors of Replimune Group Inc. (NASDAQ: REPL), Mnemo Therapeutics, Umoja Biopharma, Inc., Inspirna, Inc., and Ziel Bio, Inc.
  • Previously, Mr. Weinand was Chief Executive Officer and Chairman of the Board of Bayer Pharma AG and member of the Management Board at Bayer AG.
  • Prior to his work at Bayer, Mr. Weinand held various positions in commercial, operational, and strategic areas of the pharmaceutical industry.

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer's Disease

Retrieved on: 
Wednesday, June 7, 2023
SAB, Houston Methodist Hospital, Clinical Dementia Rating, Alzheimer's disease, Serum, CCL11, CCL2, Alzheimer's Association, PET, IL-6, Brain, Melinda French Gates, Biomarker, Inflammation, Dementia, Trial of the century, COYA, Cerebral cortex, Cognitive Function Scanner, ADAS-Cog, Bill & Melinda Gates Foundation, Patient, Blood, Interleukin 6, Microglia, Cytokine, Mini–Mental State Examination, Therapy, Positron emission tomography, Nerve, MMSE, ALS, Conference, Interleukin, Neuroinflammation, Pharmaceutical industry, Vaccine, Medical imaging, TSPO

- Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation.

Key Points: 
  • - Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation.
  • Meaningful reductions in neuroinflammation were observed throughout the cerebral cortex including hippocampal regions following treatment with COYA 301, which correlated with improvement in cognitive function in this patient.
  • The patients were treated with five day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment.
  • "We believe these additional data further support our Treg-focused approach to develop safe and effective treatments for neurodegenerative diseases of high unmet need.

Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Oncology, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, POC, Senior, American Neurological Association, CC, Muscular dystrophy, PET, IL-6, Brain, Research, Houston Methodist Hospital, Dementia, CCL4, COYA, Cerebral cortex, Regulatory T cell, Biology, AAIC, Uneme language, HIV disease progression rates, Patient, Master of Science, Blood, Regulatory affairs, Regulation, Next Generation, AD, FDA, Therapy, R, Positron emission tomography, IND, MMSE, Conference, Interleukin, Safety, Neuroinflammation, Pharmaceutical industry, Cryptocurrency, ALS, MD

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update.
  • Study data were presented at the 2023 Keystone Symposia Neurodegeneration: Biology Guiding the Next Generation of Therapeutic Development.
  • COYA 301 is Coya’s proprietary ld IL-2 formulation that is intended to enhance anti-inflammatory regulatory T cell function and numbers.
  • The Company expects general and administrative costs to continue to grow in 2023 as Coya expands its business development activities as well as incur additional public company costs.

Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

Retrieved on: 
Thursday, August 3, 2023
Science, Neurology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, COYA, Therapy, Conference, Direct Corporate Access, Pharmaceutical industry

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced that Dr. Fred Grossman, President and Chief Medical Officer, is presenting at BTIG’s Virtual Biotechnology Conference 2023, Tuesday, August 8th at 1:30 p.m.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced that Dr. Fred Grossman, President and Chief Medical Officer, is presenting at BTIG’s Virtual Biotechnology Conference 2023, Tuesday, August 8th at 1:30 p.m.
  • ET.
  • This conference is being hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services.
  • BTIG’s Corporate Access program hosts client events across the consumer, digital assets, energy and infrastructure, financials, healthcare, real estate and technology sectors.

Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Wednesday, July 19, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Merit Cudkowicz, International, Harvard–MIT Program in Health Sciences and Technology, Life, Outline of health sciences, Clinical trial, American Academy, Boston, COYA, Forbes Norris, Harvard Medical School, National Institute of Neurological Disorders and Stroke, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, DSM-IV codes, Massachusetts Institute of Technology, Public health, Beth Israel Hospital, Patient, Coya, Chemical engineering, Master of Science, Hospital, American Academy of Neurology, Massachusetts General Hospital, Therapy, ALS, Harvard School of Dental Medicine, Commerce, Pharmaceutical industry, MD

Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.

Key Points: 
  • Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.
  • Dr. Cudkowicz brings decades of experience supporting the development of new therapies for ALS.
  • Dr. Cudkowicz has launched the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that helps accelerate therapy development in ALS.
  • Merit Cudkowicz commented: "I am happy to join Coya as a clinical advisor as they move COYA 302 into a well powered and designed clinical trial.

Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease

Retrieved on: 
Monday, July 17, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Houston Methodist Hospital, Serum, Melinda French Gates, Biomarker, Inflammation, Dementia, CCL4, COYA, Cognitive Function Scanner, ADAS-Cog, Bill & Melinda Gates Foundation, AAIC, Patient, Coya, Blood, FLT3LG, Poster, Chemokine, AD, Therapy, Conference, MMSE, SD, Safety, Pharmaceutical industry, Regulatory T cell

The study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25.

Key Points: 
  • The study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25.
  • The patients were treated with five-day-courses of subcutaneous ld IL-2 for four monthly cycles and were followed for two months post-treatment.
  • The additional blood biomarker data showing a significant decrease in the blood levels of the proinflammatory cytokines and chemokines CCL4, FLT3LG and TNFα in AD patients treated with ld IL-2 strengthen the positive results Coya has previously announced in May 2023.
  • Our 8 patient study in AD was safe and well tolerated, decreased pro-inflammatory signaling, and suggested a beneficial clinical effect.

Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner

Retrieved on: 
Wednesday, July 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, BSE, Glenmark Pharmaceuticals, Sunovion, Mesoblast, Bristol Myers Squibb, COYA, Eli Lilly, Patient, Coya, Amyotrophy, Johnson & Johnson, Therapy, Team, Inflammation, Pharmaceutical industry, Medical device, ALS

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Fred Grossman to its senior management team as President and Chief Medical Officer.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Fred Grossman to its senior management team as President and Chief Medical Officer.
  • Prior to joining Coya, Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion.
  • He also previously served as Chief Medical Officer at Mesoblast, Inc. (NASDAQ: MESO), developing allogeneic cellular therapies for inflammatory diseases.
  • We also welcome Dr. Grossman, who brings decades of clinical development experience and successful execution,” stated Howard H. Berman, Ph.D., CEO of Coya Therapeutics.